Association of vitamin D3 with psoriasis and psoriatic arthritis-an observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20231605Keywords:
25 (OH) vit D3, Psoriasis, Psoriatic arthritis, Psoriatic area, Disease severity index, DAS28 scoreAbstract
Background: The objective of this study is to investigate the association between 25 (OH) vit D3 level and psoriasis, in our city with long sunny weather, in an attempt to clarify the controversies.
Methods: The 100 patients with psoriasis including 29 with psoriatic arthritis were taken randomly as cases from medicine outpatient department of KPCMCH. Psoriasis area and severity index (PASI) was calculated for all patients with psoriasis and disease activity score (DAS28-CRP) in all arthritis patients. The control group had 150 age and sex-matched participants without any symptoms related to psoriasis or psoriatic arthritis. The 25 (OH) vit D3 serum level was estimated for both groups. This is an observational, cross-sectional study.
Results: Out of total 100 patients, 55% were male and 45% female, with mean age and disease duration 49.7±6.7 years and 11.4±3.5 years, respectively. The control group had 150 subjects (86 males, 64 females). The 25 (OH) vit D3 levels of both patients and controls were 19.2±8.5 ng/ml and 29.9±6.7 ng/ml, respectively and the difference was statistically significant (p<0.05). The 25(OH) vit D3 levels were 21.9±4.1 ng/ml in patients with disease duration <10 years, and 15.9±4.2 ng/ml in patients with disease duration ≥ 10 years and difference was statistically significant (p<0.05). It was 18.9±7.8 ng/ml and 20.1±8.4 ng/ml respectively in psoriasis patients with and without arthritis but the difference was statistically not significant (p>0.05). The 25(OH) vit D3 level was lower in psoriasis with high PASI compared to psoriasis with low-moderate PASI and lower in psoriatic arthritis with high disease activity compared to arthritis with low-moderate disease activity.
Conclusions: Both psoriasis and psoriatic arthritis patients had lower 25 (OH) vit D3 levels. The disease durations were directly related to 25 (OH) vit D3 insufficiency. Lower levels were associated with higher active diseases.
Metrics
References
Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N et al. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893-901.
Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail psoriasis: An updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2019;99:516-23.
Allayali A, Niaz G, Al Hawsawi K, Fatani M, Siddiqui I, Baghdadi R et al. Association between Vitamin D deficiency and psoriasis: A case-control study. J Clin Exp Dermatol Res 2018;9:1000442.
Sankowski AJ, Łebkowska UM, Ćwikła J, Walecka I, Walecki J. Psoriatic arthritis. Polish J Radiol. 2013;78:7-17.
Dos M, Diniz S, Pinto JM, Marta M, Soares S. Serum levels of 25-OH Vitamin D in psoriatic patients and control subjects. JOJ Dermatol Cosmet. 2019;1:65-8.
Hallak A, Malhis M, Abajy MY. Vitamin-D deficiency and risk of acute coronary syndrome. Int J Pharm Pharm Sci. 2018;10:171.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1-28.
García de Tena J, Abejón L, Horcajo P. Vitamin D insufficiency. N Engl J Med. 2011;364:248-54.
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64:65-8.
Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.
Mattozzi C, Paolino G, Richetta AG, Calvieri S. Psoriasis, Vitamin D and the importance of the cutaneous barrier’s integrity: An update. J Dermatol. 2016;43:507-14.
Mostafa WZ, Hegazy RA. Vitamin D and the skin: Focus on a complex relationship: A review. J Adv Res. 2013;6:793-804.
Kamangar F, Koo J, Heller M, Lee E, Bhutani T. Oral Vitamin D, still a viable treatment option for psoriasis. J Dermatol Treat. 2013;24:261-7.
Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G et al. Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol. 2012;166:505-10.
Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. J Am Acad Dermatol. 2012;67:931-8.
Ibrahim A, Ltamimy H, Rayan M, Abdul-Hamied H. Measurement of Vitamin D and Its relation to psoriatic arthritis. Al Azhar Assiut Med J. 2013;11:292-304.
Touma Z, Eder L, Zisman D, Feld J, Chandran V, Rosen CF et al. Seasonal variation in Vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care Res. 2011;63:1440-7.
Filoni A, Vestita M, Congedo M, Giudice G, Tafuri S, Bonamonte D. Association between psoriasis and Vitamin D: Duration of disease correlates with decreased Vitamin D serum levels: An observational case-control study. Medicine (Baltimore). 2018;97:10-3.
Beata BC, Ligia BW. Serum Vitamin D level-the effect on the clinical course of psoriasis. Postep Dermatol Alergol. 2016;33:445-9.
Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9:302-9.
Chandrashekar L, Kumari GR, Rajappa M, Revathy G, Munisamy M, Thappa DM. 25-hydroxy Vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br J Biomed Sci. 2015;72:56-60.
Mattozzi C, Paolino G, Salvi M, Macaluso L, Scarnò M, De Vita G et al. Correlation between plasmatic levels of Vitamin D and PASI score. G Ital Dermatol Venereol. 2018;153:155-60.
Downloads
Published
How to Cite
Issue
Section
